Sumitomo Mitsui Trust Group Inc. Acquires 2,521 Shares of United Therapeutics Corporation $UTHR

Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 2.6% in the 2nd quarter, Holdings Channel.com reports. The fund owned 100,248 shares of the biotechnology company’s stock after purchasing an additional 2,521 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in United Therapeutics were worth $28,806,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. First Citizens Bank & Trust Co. raised its stake in shares of United Therapeutics by 92.7% during the second quarter. First Citizens Bank & Trust Co. now owns 5,007 shares of the biotechnology company’s stock valued at $1,439,000 after acquiring an additional 2,408 shares during the last quarter. Forum Financial Management LP increased its position in shares of United Therapeutics by 5.5% during the second quarter. Forum Financial Management LP now owns 1,390 shares of the biotechnology company’s stock worth $399,000 after buying an additional 72 shares during the period. Ethic Inc. increased its position in shares of United Therapeutics by 13.0% during the second quarter. Ethic Inc. now owns 901 shares of the biotechnology company’s stock worth $256,000 after buying an additional 104 shares during the period. Rehmann Capital Advisory Group increased its position in shares of United Therapeutics by 19.1% during the second quarter. Rehmann Capital Advisory Group now owns 2,170 shares of the biotechnology company’s stock worth $624,000 after buying an additional 348 shares during the period. Finally, TFB Advisors LLC increased its position in shares of United Therapeutics by 32.0% during the second quarter. TFB Advisors LLC now owns 4,021 shares of the biotechnology company’s stock worth $1,155,000 after buying an additional 975 shares during the period. Institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total value of $9,396,900.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $11,356,133.75. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 349,435 shares of company stock worth $144,451,272 over the last ninety days. Insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of United Therapeutics in a research report on Monday, October 20th. They set an “underweight” rating and a $414.00 price objective for the company. Morgan Stanley increased their price objective on shares of United Therapeutics from $328.00 to $435.00 and gave the stock an “equal weight” rating in a research report on Friday, October 10th. Cantor Fitzgerald increased their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Jefferies Financial Group increased their price objective on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Finally, Royal Bank Of Canada assumed coverage on shares of United Therapeutics in a research report on Friday, September 26th. They set an “outperform” rating and a $569.00 price objective for the company. Nine equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $461.62.

United Therapeutics Trading Down 1.4%

NASDAQ:UTHR opened at $415.34 on Wednesday. The stock has a market capitalization of $18.74 billion, a price-to-earnings ratio of 16.21, a PEG ratio of 4.59 and a beta of 0.66. The firm has a fifty day simple moving average of $401.57 and a two-hundred day simple moving average of $334.83. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $459.48.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. During the same period last year, the business posted $5.85 earnings per share. The firm’s quarterly revenue was up 11.7% on a year-over-year basis. Equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.